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1. INTRODUCTION {#ejh13247-sec-0005}
===============

Overall survival (OS) in adult acute lymphoblastic leukaemia (ALL) has improved over the last decades. A population‐based study from the Netherlands with patients with ALL diagnosed from 1989 to 2012 revealed improved survival for all patients younger than 70 years.[1](#ejh13247-bib-0001){ref-type="ref"} The 5‐year OS was 75% for patients 18‐24 years but only 37% for patients between 40 and 59 years in recent years, a finding confirmed by others.[2](#ejh13247-bib-0002){ref-type="ref"}, [3](#ejh13247-bib-0003){ref-type="ref"}, [4](#ejh13247-bib-0004){ref-type="ref"}, [5](#ejh13247-bib-0005){ref-type="ref"}

The improvement in OS seen in younger adults (predominantly in Philadelphia‐negative \[Ph‐neg\] ALL) has been connected to the introduction of paediatric‐inspired protocols with multidrug induction, high‐dose methotrexate and asparaginase, as well as risk‐adapted treatment according to disease‐ and response‐related factors.[1](#ejh13247-bib-0001){ref-type="ref"}, [6](#ejh13247-bib-0006){ref-type="ref"}, [7](#ejh13247-bib-0007){ref-type="ref"} The toxicity profile has been found acceptable, at least to the age of 45 years.[6](#ejh13247-bib-0006){ref-type="ref"}, [8](#ejh13247-bib-0008){ref-type="ref"}, [9](#ejh13247-bib-0009){ref-type="ref"} Later reports indicate that age‐adapted paediatric‐inspired therapy is feasible up to the age of 65 years.[10](#ejh13247-bib-0010){ref-type="ref"} In Philadelphia‐positive (Ph‐pos) ALL, the introduction of tyrosine kinase inhibitors (TKI) has fundamentally changed clinical practice and rendered improved OS both with and without allogeneic hematopoietic stem cell transplantation (HSCT).[5](#ejh13247-bib-0005){ref-type="ref"}, [11](#ejh13247-bib-0011){ref-type="ref"}, [12](#ejh13247-bib-0012){ref-type="ref"}, [13](#ejh13247-bib-0013){ref-type="ref"}, [14](#ejh13247-bib-0014){ref-type="ref"}, [15](#ejh13247-bib-0015){ref-type="ref"}

Taken together, there is convincing evidence of therapeutic advancements in the last decades. However, there is lack of knowledge on ALL outcome from population‐based studies that include information about Ph‐pos disease and allogeneic HSCT. We used the nationwide Swedish Acute Leukaemia Registry, later the Swedish ALL Registry, to investigate disease characteristics, treatment and survival in patients diagnosed with ALL between 1997 and 2015.

2. PATIENTS AND METHODS {#ejh13247-sec-0006}
=======================

2.1. The Acute Lymphoblastic Leukaemia Registry {#ejh13247-sec-0007}
-----------------------------------------------

Since 1958, both pathologists and clinicians are obliged to report every cancer at diagnose to the Swedish Cancer Registry. The dual reporting system improves coverage and accuracy. From the Cancer Registry, diagnosis‐specific quality registries have evolved. From 1997, patients with acute leukaemia were monitored in the nationwide but regionally based Acute Leukaemia Registry. In 2007, the registry became a web‐based system, divided into the Acute Myeloid Leukaemia (AML) Registry and the ALL Registry as part of the new centralised Blood Cancer Registry. The registry has been previously described in detail, and the first report on ALL incidence was published in 2010.[16](#ejh13247-bib-0016){ref-type="ref"}, [17](#ejh13247-bib-0017){ref-type="ref"}, [18](#ejh13247-bib-0018){ref-type="ref"} Different cohort studies have been performed with identification of patients from the ALL Registry, but an analysis of the complete registry has never been published.[19](#ejh13247-bib-0019){ref-type="ref"}, [20](#ejh13247-bib-0020){ref-type="ref"}, [21](#ejh13247-bib-0021){ref-type="ref"}

Into the ALL Registry, the treating physicians prospectively report different variables (these have expanded over time) including date of diagnosis, WHO performance status (WHO‐PS), treatment intention (remission inducing or palliative approach), date of first complete remission (CR1) and allogeneic HSCT. Ideally, it includes annual reports on last date of follow‐up and any date of relapse. Vital status is updated from the Swedish Civil Citizen Registry. Registry monitoring is done by regional controllers, and a written national report is regularly compiled. The completion of the diagnosis registration form compared to the Cancer Registry was 100% for patients with ALL diagnosis between 2007 and 2012 and 98% for 2013 and 2014.[22](#ejh13247-bib-0022){ref-type="ref"}

The database for this study was merged from the "old" (1997‐2006) Acute Leukaemia Registry and the "new" (2007‐2015) ALL Registry with some variables recoded to enable overall analysis. Definitions are described in Data [S1](#ejh13247-sup-0004){ref-type="supplementary-material"}. Because some variables were only reported in the new registry, they were analysed solely for this period. No verification of the ALL diagnosis was done beyond the dual reporting system.

2.2. Genetic analysis {#ejh13247-sec-0008}
---------------------

Since 2007, Ph‐pos disease was reported in the registry even though as early as 1997 Ph‐pos leukaemia was considered a high‐risk criterion in the national guidelines. The recommended methods of investigation were conventional cytogenetics, fluorescent in situ hybridization (FISH) and/or polymerase chain reaction (PCR).

In this study, the reported genetic analysis was validated and missing data were collected from the six central genetic laboratory facilities performing the analysis in Sweden. Patients not confirmed to be Ph‐pos ALL are labelled Ph‐neg ALL in this text---except when calculating Ph frequency and OS for B‐ALL. In the latter two analyses, patients not adequately examined (defined as normal karyotype with ≥20 metaphases, another karyotype with clonal abnormality, a negative FISH or a negative PCR for major and minor transcript) were considered to have missing data (details in Data [S1](#ejh13247-sup-0004){ref-type="supplementary-material"}).

2.3. Treatment {#ejh13247-sec-0009}
--------------

Treatment recommendations, as part of national guidelines, changed over time (details in Data [S1](#ejh13247-sup-0004){ref-type="supplementary-material"} and Table [S1](#ejh13247-sup-0001){ref-type="supplementary-material"}). In brief, the Swedish protocol ABCDV/VABA was the main remission‐inducing protocol.[23](#ejh13247-bib-0023){ref-type="ref"} After a pilot study, patients 18‐45 years with Ph‐neg ALL were treated according to the paediatric NOPHO ALL 2008 protocol.[24](#ejh13247-bib-0024){ref-type="ref"} Hyper‐CVAD was recommended for T‐ALL cases between 2003 and 2009.[25](#ejh13247-bib-0025){ref-type="ref"} For patients with Burkitt leukaemia, the NHL‐BFM‐90 protocol and subsequently the GMALL‐B‐ALL/NHL2002 were advocated.[26](#ejh13247-bib-0026){ref-type="ref"}, [27](#ejh13247-bib-0027){ref-type="ref"} For older patients, age‐adopted protocols such as the EWALL‐backbone were suggested.[15](#ejh13247-bib-0015){ref-type="ref"} Addition of imatinib to chemotherapy backbones for Ph‐pos ALL was formally recommended in 2007 but was gradually introduced the years before.

2.4. Statistics {#ejh13247-sec-0010}
---------------

Fischer\'s exact test was used to compare categorical variables. Continuous variables were analysed with the Mann--Whitney *U* test. Survival was estimated using the Kaplan‐Meier method and differences compared with the log‐rank test. Univariable and multivariable Cox Regression analyses were used to determine hazard ratio (HR) of covariates included in the multivariable model.

Standardised mortality ratio (SMR) was calculated using indirect standardisation. Patients who had survived 5 years from ALL diagnosis were compared with the expected number of deaths in the Swedish population between 2002 and 2018. Patients were matched based on age, gender and calendar year at risk. When needed, the expected number of deaths was adjusted to account for incomplete follow‐up time at calendar year.

Because no imputation of missing data was done and no adjustment for multiplicity testing was performed, *P*‐values should be interpreted as explorative. Statistical analyses were performed with the SPSS‐software (IBM) v24 and v25 and R version 3.5.2 (R Core Team).

Vital status was followed until 31 May 2018. The study was approved by the regional ethical committee, Uppsala (Dnr 2016/349) and conducted in accordance with the Declaration of Helsinki.

3. RESULTS {#ejh13247-sec-0011}
==========

3.1. Patients {#ejh13247-sec-0012}
-------------

We identified 937 patients 18 years or older diagnosed with ALL between 1997 and 2015. Three patients were excluded due to a known Philadelphia chromosome one, two and 6 years before ALL diagnosis as these patients were judged to have chronic myeloid leukaemia in lymphatic blast crisis. One patient was excluded because of a relapse of childhood leukaemia.

Patient characteristics of the remaining 933 patients are presented in Table [1](#ejh13247-tbl-0001){ref-type="table"}. The B‐ALL cohort comprised 68%, T‐ALL 15% and Burkitt leukaemia 4%. The group of ALL Not Otherwise Specified (NOS) diminished from 22% in the old to 5% in the new registry.

###### 

Patient characteristics of the 933 patients divided by phenotype for the whole study period (1997‐2015) and in the new more detailed registry (2007‐2015)

  Variable name                                   All patients   Ph‐neg B‐ALL   Ph‐pos ALL   Ph‐pos ALL vs Ph‐neg B‐ALL   T‐ALL     T[a](#ejh13247-note-0003){ref-type="fn"} ‐ALL vs Ph‐neg B‐ALL   Burkitt leukaemia   Burkitt vs Ph‐neg B‐ALL   ALL NOS   ALL NOS vs Ph‐neg B‐ALL                                                        
  ----------------------------------------------- -------------- -------------- ------------ ---------------------------- --------- --------------------------------------------------------------- ------------------- ------------------------- --------- ------------------------- --------- --------- ------------- -------- --------- -------------
  Patients, n                                     933                           468                                       176                                                                                           135                                                           41                                122                 
  New/Old registry, n, (%)                        469/464        50/50          237/231      51/49                        110/66    63/37                                                                               79/56                     59/41                               25/16     61/39                   22/100   18/82      
  Age, years, median, range                       53             18‐95          54           18‐94                        53        19‐87                                                           n.s                 37                        18‐89     *P \< 0.01*               61        19‐87     *P = 0.03*    64       18‐95     *P* \< 0.01
  Male/Female, n, (%)                             522/411        56/44          241/227      52/48                        92/84     52/48                                                           n.s                 100/35                    74/26     *P \< 0.01*               25/16     61/39     n.s           67/55    55/45     n.s
  B‐ALL, n, (%)                                   635            68             468          100                          167       95                                                                                                                                                                                                      
  T‐ALL, n, (%)                                   135            15                                                       1         1                                                                                   135                       100                                                                                       
  Burkitt leukaemia, n, (%)                       41             4                                                        0         0                                                                                                                                                 41        100                                         
  ALL NOS, n (%)                                  122            13                                                       8         4                                                                                                                                                                                   122      100        
  WHO‐PS, n (%)                                                                                                                                                                                                                                                                                                                            
  0                                               214            23             99           21                           48        27                                                                                  41                        30                                  5         12                      24       20         
  1                                               467            50             250          54                           90        51                                                                                  74                        55                                  11        27                      45       37         
  2                                               122            13             66           14                           20        11                                                                                  7                         5                                   8         19                      23       19         
  3                                               65             7              29           6                            8         5                                                                                   3                         2                                   11        27                      14       11         
  4                                               40             4              14           3                            1         1                                                                                   6                         5                                   6         15                      13       11         
  Missing                                         25             3              10           2                            9         5                                                                                   4                         3                                                                     3        2          
  Variables only in the new registry 2007‐2015                                                                                                                                                                                                                                                                                             
  WBC ×10^9^/L, median, range                     13             0.4‐904        6            0.4‐904                      29        0.7‐477                                                         *P* \< 0.01         33                        1.3‐477   *P* \< 0.01               14        2.5‐89    *P* \< 0.01   7        0.6‐236   n.s
  Haemoglobin, g/L, median, range                 103            49‐180         99           50‐161                       103       56‐180                                                          n.s                 118                       49‐164    *P* \< 0.01               109       82‐158    *P* \< 0.01   106      66‐139    n.s
  Platelet count, ×10^9^/L, median, range         54             2‐1306         56           3‐409                        46        2‐1306                                                          n.s                 68                        11‐360    n.s                       51        8‐257     n.s           53       10‐522    n.s
  CNS‐leukaemia involvement, normal, NA, n, (%)   21;350;98      5;75;20        7;180;50     3;76;21                      5;83;22   5;75;20                                                                             6;61;12                   8;77;15                             2;13;10   8;52;40                 1;17;4   5;77;18    

Abbreviations: ALL, acute lymphoblastic leukaemia; CNS, central nervous system; NA, not available; NOS, not otherwise specified; Ph‐pos, Philadelphia‐positive; Ph‐neg, Philadelphia‐negative; WBC, white blood cell count; WHO‐PS, WHO Performance status.

Excluding the one patient with Ph‐pos T‐ALL.

John Wiley & Sons, Ltd

Median age at ALL diagnosis was 53 years (range 18‐95 years) and was similar for Ph‐pos (53 years) and Ph‐neg B‐ALL (54 years). As expected, the T‐ALL cohort was younger (37 years) and mainly male. Burkitt and ALL NOS patients were significantly older (61 and 64 years) than the Ph‐neg B‐ALL. The WHO‐PS was 0‐1 in 73% of patients and 2 or more in 24%.

3.2. Frequency of Philadelphia‐positive ALL {#ejh13247-sec-0013}
-------------------------------------------

Information about Ph‐pos disease was reported only in the new registry and therefore retrospectively collected for the old registry as mentioned above and in Data [S1](#ejh13247-sup-0004){ref-type="supplementary-material"}. Testing for Ph‐pos ALL increased over time from 59% in 1997‐2007 (272 of 464) to 88% in 2007‐2015 (411 of 469; *P* \< 0.01). Of the 933 patients in the registry, 176 patients (19%) were confirmed to be Ph‐pos ALL (one T‐ALL, eight ALL NOS and the rest of B‐ALL phenotype). In the examined cohort, the incidence of Ph‐pos ALL was 26% and equivalent in the two registry periods (24% in 1997‐2006: 66 of 272 tested, 192 not tested/missing data; 27% in 2007‐2015: 110 of 411 tested, 58 not tested/missing data, *P* = ns). In examined B‐ALL (1997‐2015), the incidence was 34% (n = 635 B‐ALL; 167 Ph‐pos, 331 Ph‐neg and 137 with missing data). The Ph frequencies for different age cohorts are displayed in Figure [1](#ejh13247-fig-0001){ref-type="fig"}. The highest incidence (47%) was found in patients 50‐59 years and did not increase further with age.

![Philadelphia‐positive disease of tested B‐ALL in different age groups](EJH-103-88-g001){#ejh13247-fig-0001}

3.3. Descriptive variables only reported in the new registry 2007‐2015 {#ejh13247-sec-0014}
----------------------------------------------------------------------

The median white blood cell count (WBC) was higher in the Ph‐pos cohort as well as in the T‐ALL cohort compared with Ph‐neg B‐ALL (Table [1](#ejh13247-tbl-0001){ref-type="table"}). Of Ph‐neg B‐ALL, 24% had a WBC of ≥30 × 10^9^/L and 34% of T‐ALL patients had WBC of ≥100 × 10^9^/L. Information about bulky disease was available for 425 (91%) patients and present in 25 patients (19 cases in T‐ALL \[27% of 71 reported\] and the remaining in B‐ALL \[n = 1\], Burkitt \[n = 2\] and ALL NOS \[n = 3\]).

3.4. Treatment and outcome {#ejh13247-sec-0015}
--------------------------

Survival analyses were done with patients divided into three age groups (18‐45, 46‐65 and \>65 years) and for two time periods (1997‐2006 and 2007‐2015). Unless otherwise stated, comparisons between Ph‐pos and Ph‐neg ALL are done without further subgrouping.

3.5. Remission intention and early deaths {#ejh13247-sec-0016}
-----------------------------------------

Details are described in Table [2](#ejh13247-tbl-0002){ref-type="table"}. Intensive remission‐inducing chemotherapy was intended in 89% of patients and did not increase over time. In the total cohort (n = 930, excluding three without the exact date of diagnosis), 10% died within 30 days and 14% died within 60 days from diagnosis. For patients with remission as the treatment goal, deaths within 30 days diminished from 7% (30/405) in 1997‐2006 to 3% (12/420) in 2007‐2015 (*P* \< 0.05). Death within 60 days decreased from 11% (45/405) to 6% (27/420) (*P* \< 0.05). In patients without remission intention (median age 80 years, the majority not evaluated for Ph status), 44% (44/101) died within 30 days from diagnosis, which did not change over time.

###### 

Treatment intention, early deaths and complete remission rates for the whole study period (1997‐2015) and in the new, more detailed registry (2007‐2015) including treatment regimens

                                                                                                                          All patients     18‐45 y      46‐65 y         \>65 y                                                     
  ----------------------------------------------------------------------------------------------------------------------- ---------------- ------------ --------------- ------------ --------------- ------------- --------------- -------------
  Remission‐inducing Therapy Intended                                                                                                                                                                                              
  Yes; No (total)[a](#ejh13247-note-0005){ref-type="fn"}                                                                  827; 102 (929)   89; 11       380; 1 (381)    100; 0       258; 6 (264)    98; 2         189; 95 (284)   67; 33
  Ph‐pos ALL, Remission Inducing Yes; No                                                                                  169; 7           96; 4        66; 0           100; 0       65; 0           100; 0        38; 7           84; 16
  Ph‐neg ALL, Remission Inducing Yes; No                                                                                  658; 95          87; 13       314; 1          100; 0       193; 6          97; 3         151;88          63; 37
  CR achieved                                                                                                                                                                                                                      
  Yes; No (total) (if Remission‐inducing Therapy Intended)                                                                694; 91 (785)    88           358; 11 (369)   97           217; 28 (245)   89            119; 52 (171)   70
  Death within 30 d of diagnosis[b](#ejh13247-note-0006){ref-type="fn"}                                                                                                                                                            
  Total (Remission Inducing; Not remission inducing)                                                                      86 (42; 44)      9 (5; 44)    5 (4; 1)        1 (1; 100)   17 (15; 2)      6 (6; 33)     64 (23; 41)     23 (12; 44)
  Death within 60 d of diagnosis                                                                                                                                                                                                   
  Total (Remission‐inducing; Not remission inducing)                                                                      131 (72; 59)     14 (9; 58)   7 (6; 1)        2 (2; 100)   27 (25; 2)      10 (10; 33)   97 (41; 56)     35 (22; 60)
  Variables only in the new registry 2007‐2015 Regimens reported[c](#ejh13247-note-0007){ref-type="fn"} and CR achieved                                                                                                            
  Intensive guidelines[d](#ejh13247-note-0008){ref-type="fn"} ± imatinib CR Yes; No (total)                               191; 16 (207)    92           77; 1 (78)      99           87; 5 (92)      95            27; 10 (37)     73
  NOPHO‐protocol 1992 or 2008, CR Yes; No (total)                                                                         114; 1 (115)     99           107; 1 (108)    99           7; 0 (7)        100           0                
  Age‐adopted ± imatinib CR Yes; No (total)                                                                               42; 14 (56)      75           0                            4; 3 (7)        57            38; 11 (49)     78
  GMALL CR Yes; No (total)                                                                                                15; 4 (19)       79           7; 0 (7)        100          3; 1 (4)        75            5; 3 (8)        63

Abbreviations: ALL, acute lymphoblastic leukaemia; CR, complete remission; Ph‐pos, Philadelphia‐positive; Ph‐neg, Philadelphia‐negative.

Four patients with missing data on remission intention, total n = 929.

Three patients with missing data on the exact date of diagnosis, total n = 926.

Regimens reported; for references, see Data S1.

Instructions for registration of treatment has changed over time and the exact intensive therapy given has not always been possible to report.

John Wiley & Sons, Ltd

3.6. Treatment intensity and complete remission {#ejh13247-sec-0017}
-----------------------------------------------

In the old registry, information about given treatment was restricted to (a) intensive/remission‐inducing, (b) palliative chemotherapy or (c) no treatment/supportive care. In the new registry, more detailed information was collected (Table [2](#ejh13247-tbl-0002){ref-type="table"}). Of the patients with information about CR status and intention to treat into remission, 88% reached a CR1. In patients 18‐45, 46‐65 and \>65 years, the CR rates were 97%, 89% and 70%, respectively (Table [2](#ejh13247-tbl-0002){ref-type="table"}).

3.7. Overall survival {#ejh13247-sec-0018}
---------------------

Five‐year OS improved in all age groups and increased from 50% (95% CI 43‐57) to 65% (95% CI 58‐72) in patients 18‐45 years, from 25% (95% CI 18‐32) to 46% (95% CI 37‐55) in patients 46‐65 years and from 7% (95% CI 2.6‐11) to 11% (95% CI 5.9‐16) in patients \>65 years (*P *= \<0.05, log‐rank for pairwise comparison; Figure [2](#ejh13247-fig-0002){ref-type="fig"}). The corresponding median OS increased from 5.0 years (95% CI 1.3‐8.7) to the median OS not yet reached, from 1.4 years (95% CI 1.0‐1.8) to 3.6 years (95% CI 0.9‐6.2) and from 0.2 years (95% CI 0.1‐0.4) to 0.6 years (95% CI 0.4‐0.8) for the three age groups and the two time periods, respectively.

![Overall survival in the total cohort (n = 930) in 1997‐2006 and 2007‐2015. Five‐year overall survival improved in patients 18‐45 y from 50% (95% CI 43‐57) to 65% (95% CI 58‐72), in patients 46‐65 y from 25% (95% CI 18‐32) to 46% (95% CI 37‐55), and in patients \>65 y from 7% (95% CI 2.6‐11) to 11% (95% CI 5.9‐16) (*P *= \<0.05, log‐rank for pairwise comparison) \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](EJH-103-88-g002){#ejh13247-fig-0002}

When divided into Ph‐neg and Ph‐pos ALL, OS improved in all groups (*P* \< 0.05 for pairwise comparison, log‐rank) except for Ph‐neg patients \>65 years (*P* = ns, log‐rank; Figure [3](#ejh13247-fig-0003){ref-type="fig"}A and B). In Ph‐pos ALL, only borderline significance was seen in patients 46‐65 years (*P* = 0.05, log‐rank; Figure [4](#ejh13247-fig-0004){ref-type="fig"}A and B).

![Overall survival (OS) in Philadelphia‐negative ALL in 1997‐2006 and 2007‐2015. A, Five‐year OS 1997‐2006 in patients 18‐45 y was 50% (95% CI 43‐58), in patients 46‐65 y 25% (95% CI 18‐33) and in patients \>65 7% (95% CI 2‐12). B, Five‐year OS 2007‐2015 in patients 18‐45 y was 65% (95% CI 58‐73), in patients 46‐65 y 42% (95% CI 31‐53) and in patients \>65 y 9% (95% CI 4‐15) \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](EJH-103-88-g003){#ejh13247-fig-0003}

![Overall survival (OS) in Philadelphia‐positive ALL in 1997‐2006 and 2007‐2015. A, Five‐year OS 1997‐2006 in patients 18‐45 y was 48% (95% CI 30‐67), in patients 46‐65 y 24% (95% CI 7‐41) and in patients \>65 y 0%. B, Five‐year OS 2007‐2015 in patients 18‐45 y was 64% (95% CI 47‐81), in patients 46‐65 y 56% (95% CI 40‐72) and in patients \>65 y 18% (95% CI 5‐31) \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](EJH-103-88-g004){#ejh13247-fig-0004}

Five‐year OS divided by phenotype and age group is presented in Table [S2](#ejh13247-sup-0002){ref-type="supplementary-material"}.

The standardised mortality ratio (SMR) was 5.7 (95% CI 5.0‐6.3) for patients that had survived 5 years from diagnosis (SMR---the number of deaths in the study cohort compared to the age‐adjusted expected deaths in the general population). The SMR decreased from 6.5 (95% CI 5.8‐7.8) to 3.8 (95% CI 2.8‐5.2) between 1997‐2006 and 2007‐2015, respectively. Median follow‐up for these patients in the SMR analysis was 10.7 years from diagnosis. Further subgroup analyses were not performed because of the size of the material.

3.8. Allogeneic stem cell transplantation {#ejh13247-sec-0019}
-----------------------------------------

Of the 827 patients in which treatment intention was remission‐inducing, 24% (n = 200) were reported allografted in CR1 and 46% of them had Ph‐pos ALL. The HSCT frequency in patients 18‐45 years was 35% (64/182) versus 32% (64/198) in 1997‐2006 and 2007‐2015, respectively (*P* = ns). In patients 46‐65 years, it increased from 21% (30/141) to 33% (39/117; *P* = 0.03), and in patients \>65 years, no patient was allografted in 1997‐2006 and only 3% (3/105) in 2007‐2015. The corresponding 5‐year OS improved for patients 18‐45 years from 50% (95% CI 37‐62) to 66% (95% CI 54‐78; *P* = 0.01, log‐rank) and for patients 46‐65 years from 30% (95% CI 14‐46) to 60% (95% CI 43‐76; *P* = 0.05, log‐rank). The three patients over 65 years transplanted in 2007‐2015 were all deceased within 3 years of diagnosis. There was no difference in OS between Ph‐pos and other patients with ALL allografted in CR1 (*P* = ns).

3.9. Prognostic factors {#ejh13247-sec-0020}
-----------------------

To evaluate the impact of different variables on OS, univariable and multivariable analyses were done for the entire registry and for the later time period (2007‐2015) and are presented in Table [S3](#ejh13247-sup-0003){ref-type="supplementary-material"}. Known risk factors such as age and WHO‐PS were related to an increased risk of death. Ph‐positivity did not impair prognosis when looking at the whole cohort and was even associated with better OS in 2007‐2015. Survival was superior in patients receiving ALL diagnosis in 2007‐2015. Allogeneic HSCT in CR1 did not have a prognostic impact. No difference in OS was found between men and women in the total cohort or for the different phenotypes in the univariable analysis. Therefore, these were not included in multivariable analysis.

However, in patients 46‐65 years, males had inferior survival compared with women (5‐year OS 26% \[95% CI 18‐34\] versus 44% \[95% CI 35‐52\], *P* \< 0.01, log‐rank). The difference was present in both time periods, but subgroup analysis revealed that the difference was significant only in the Ph‐neg B‐ALL cohort (n = 130); 5‐year OS for men was 20% (95% CI 9.7‐30) and for women 52% (95% CI 40‐64; *P* \< 0.01, log‐rank). Information about treatment and CR status was reported for 122 patients, and all but one received treatment with remission intention with a CR rate of 89% (85% for males and 93% for females, *P* = ns). There were no significant differences between sexes regarding WHO‐PS at diagnosis, median age, median WBC, proportion of patients with WBC over 30 × 10^9^/L or 100 × 10^9^/L, or HSCT frequency in CR1. Multivariable analysis within the group revealed that sex and WHO‐PS were independent factors for OS (data not shown).

4. DISCUSSION {#ejh13247-sec-0021}
=============

To our knowledge, this is the largest population‐based cohort presenting data on outcome in adult ALL including information about Ph‐pos disease and allogeneic HSCT.[1](#ejh13247-bib-0001){ref-type="ref"}, [2](#ejh13247-bib-0002){ref-type="ref"}, [3](#ejh13247-bib-0003){ref-type="ref"}, [5](#ejh13247-bib-0005){ref-type="ref"}, [28](#ejh13247-bib-0028){ref-type="ref"} An important aspect of population‐based studies is to provide aggregated clinical information that is less susceptible to the inherent selection bias of randomised controlled trials. In line with this, we present a higher median age of 53 years at ALL diagnosis and, in a study population without an upper age limit, that the median age did not differ between Ph‐pos and Ph‐neg B‐ALL.[28](#ejh13247-bib-0028){ref-type="ref"}, [29](#ejh13247-bib-0029){ref-type="ref"}, [30](#ejh13247-bib-0030){ref-type="ref"}, [31](#ejh13247-bib-0031){ref-type="ref"} As expected, T‐ALL patients were younger and we can corroborate that Burkitt leukaemia/mature B‐ALL have a substantially higher median age (61 years) than other B‐ALL.[28](#ejh13247-bib-0028){ref-type="ref"} We confirm a high frequency of Ph‐pos disease---26% of all tested patients and 34% of B‐ALL with a peak incidence in patients 50‐59 years. This is a higher frequency of Ph‐pos ALL than suggested by the landmark study of Moorman et al [28](#ejh13247-bib-0028){ref-type="ref"} but comparable to Wetzler et al[32](#ejh13247-bib-0032){ref-type="ref"} and a more recent large Italian cohort study.[33](#ejh13247-bib-0033){ref-type="ref"} On the other hand, we did not find a continuous age‐associated increase suggested in the Italian paper and by Secker‐Wetzler et al[34](#ejh13247-bib-0034){ref-type="ref"} but these studies had an upper age limit of 60 years and a low overall Ph‐pos frequency, respectively. Furthermore, the peak incidence of Ph‐pos disease in the fifth decade with a plateau between 30‐60 years is in line with Moorman and the French trial from 1996.[30](#ejh13247-bib-0030){ref-type="ref"} Because of thoroughly testing in the latter period, we suggest that our data represent and approach the true incidence and age distribution of Ph‐pos ALL in a northern European population.

In spite of a high median age in the total cohort, the intention to treat into remission was high (89%), especially in comparison with the 73% treated with curative intention in Denmark.[3](#ejh13247-bib-0003){ref-type="ref"} In younger patients, 99% received remission‐inducing therapy, and in patients \>65 years, the corresponding figure was 67%.

In Swedish AML patients, the attitude towards remission‐inducing therapy in the elderly has been shown to influence overall survival.[16](#ejh13247-bib-0016){ref-type="ref"} Whether this applies to ALL has, to our knowledge, not been studied. However, the previously low testing for Ph‐pos disease together with the 30‐day mortality of 43% patients with palliative intention (median age 80 years) indicates that there is potential to improve outcome, especially in view of the possibility to use TKI in this patient group.[35](#ejh13247-bib-0035){ref-type="ref"}

The improvement in OS in Ph‐neg patients aged 18‐45 years corresponds to the change to the use of paediatric protocols (NOPHO ALL 2008 proceeded by a pilot with NOPHO ALL 1992). For patients 46‐65 years, a similar improvement was noted. We hypothesise that better supportive care, the addition of rituximab, older patients treated according to the paediatric protocols and the use of reduced intensity conditioning in allogeneic HSCT could have been beneficial.[36](#ejh13247-bib-0036){ref-type="ref"}, [37](#ejh13247-bib-0037){ref-type="ref"}, [38](#ejh13247-bib-0038){ref-type="ref"} For the elderly Ph‐neg patients, no increase in OS was seen despite the introduction of an age‐adapted protocol.[10](#ejh13247-bib-0010){ref-type="ref"}, [21](#ejh13247-bib-0021){ref-type="ref"}

In Ph‐pos patients, OS improved in all age groups. This reflects not only the efficacy but also the good tolerance of TKI and low‐dose chemotherapy suitable for older patients.[12](#ejh13247-bib-0012){ref-type="ref"}, [14](#ejh13247-bib-0014){ref-type="ref"}, [39](#ejh13247-bib-0039){ref-type="ref"} In our previously detailed study of elderly patients from this cohort, similar outcome was seen in Ph‐pos ALL whether they were transplanted in CR1 or not at all.[21](#ejh13247-bib-0021){ref-type="ref"} In the EBMT Registry, OS was also comparable in younger Ph‐pos patients regardless if they had undergone allogeneic or autologous HSCT.[40](#ejh13247-bib-0040){ref-type="ref"}

Consequently, with the next generations of TKI it may not be necessary to use allogeneic HSCT in CR1 in younger patients with Ph‐pos ALL in deep remission. Impressive figures have been reported from the MD Anderson Institute with a 4‐year OS of 66% in patients in complete molecular remission (\<10^−4^) at three months and treated with TKI but not eligible for HSCT.[41](#ejh13247-bib-0041){ref-type="ref"} Yet, follow‐up in relation to normal life expectancy is relatively short and robust long‐term results are lacking. In our study, although 5‐year OS improved in the youngest age group, a plateau in the survival curve was seen only at that time, a finding that might be attributed to graft‐versus‐leukaemia effect in transplanted patients. We still await a randomised trial that supports cure with chemotherapy and TKI without detrimental late effects or TKI‐resistant relapses.[40](#ejh13247-bib-0040){ref-type="ref"}

When analysing prognostic factors, we confirmed that Ph‐pos disease was associated with better outcome in the later period 2007‐2015, a finding also revealed in recent studies.[5](#ejh13247-bib-0005){ref-type="ref"}, [42](#ejh13247-bib-0042){ref-type="ref"} Age, WBC count and WHO‐PS remained as high‐risk factors. This finding is well in line with both older and newer studies and might reflect the abovementioned shortage of treatments suitable for frail patients as well as clinician\'s choice of treatment intention with regard to age and WHO‐PS.[42](#ejh13247-bib-0042){ref-type="ref"}, [43](#ejh13247-bib-0043){ref-type="ref"}, [44](#ejh13247-bib-0044){ref-type="ref"}

This registry study was unable to confirm treatment‐correlated data. We suspect under‐reporting of HSCT frequency influenced the results even though our figures are almost identical with Dinmohamed et al[1](#ejh13247-bib-0001){ref-type="ref"} that presented an allogeneic HSCT frequency of 25% (in our study this was 24%) and comparable outcome with a 5‐year OS of 66% in allografted patients 18‐39 years (in our study, 5‐year OS was 66% for patients 18‐45 years transplanted between 2007 and 2015). A cautious interpretation could be that since HSCT is recommended for high‐risk patients, the treatment seems to counterbalance the risk of relapse as previously proposed, with selection bias and transplant‐related mortality as possible confounders.[37](#ejh13247-bib-0037){ref-type="ref"}, [45](#ejh13247-bib-0045){ref-type="ref"}, [46](#ejh13247-bib-0046){ref-type="ref"}

As we noticed in our previous study of older patients,[21](#ejh13247-bib-0021){ref-type="ref"} there was a pronounced difference in outcome between men and women in the Ph‐neg B‐ALL cohort of patients 46‐65 years, which we now confirm in a larger cohort and over a longer period. Inferior prognosis for males was previously reported from Poland and in historical childhood cohorts.[47](#ejh13247-bib-0047){ref-type="ref"}, [48](#ejh13247-bib-0048){ref-type="ref"} No explanation has emerged, and it is unclear whether this effect is due to the Swedish protocol ABCDV, male body mass, comorbidities or other unknown factors. Because of this and the insufficient long‐term survival in all middle‐aged patients, we have introduced a dose‐adjusted paediatric NOPHO 2008 protocol for Ph‐neg patients \>45 years without an upper chronological age limit but biological age approaching 65 years.[10](#ejh13247-bib-0010){ref-type="ref"}

The present study provides important information on nationwide standard of care, where the nearly complete coverage of reported patients compared with the compulsory cancer registry adds strength to the material. Consequently, the selection bias was reduced, which is of particular importance regarding the elderly patients that are often excluded from randomised trials. The completeness of the diagnostic forms including descriptive data was high, and the Swedish social security number system makes OS undisputable. To further secure data accuracy, we confirmed and collected Ph status at the genetic laboratories. Nevertheless, diagnostic procedures have changed over time and were not centrally reviewed or certified and all patients were not properly evaluated. Being a registry‐based database, the study depends on the accuracy of the registry forms. From a previous detailed study of older patients from this cohort, the frequency of patients with diagnosis incorrectly registered (as lymphoblastic lymphoma or lymphatic blast crisis in chronic myelogenous leukaemia) was approximately 5%.[21](#ejh13247-bib-0021){ref-type="ref"} In addition, outside randomised trials dubious diagnosis or results need to be considered and "exclusion criteria" do not exist, which leads to less stringent patient cohorts. It should also be noted that despite the high coverage and quality of vital status in the present and similar studies, follow‐up reports including HSCT and relapses are likely to be incomplete, limiting more profound analyses of, for example, treatment modalities. Nevertheless, population‐based studies are suitable as reference material when new drugs are introduced, especially if the registration trials have a narrow patient selection.[49](#ejh13247-bib-0049){ref-type="ref"}, [50](#ejh13247-bib-0050){ref-type="ref"}

Furthermore, a SMR of 5.7 in patients who had survived 5 years from ALL diagnosis elucidates that the disease and relevant treatment have consequences beyond standard end‐points. As new potent immunotherapies enter the arena, their long‐term effects need thorough follow‐up, including comparison with current standard therapies, especially when a reachable goal for the majority of patients with ALL is now long‐time survivorship.

To conclude, in an unselected northern European adult population, the Ph‐pos frequency is 26% with an equal median age for Ph‐pos and Ph‐neg B‐ALL. An improvement in OS has evolved over time, especially for Ph‐pos patients. We speculate that the use of a paediatric protocol for Ph‐neg ALL and TKI for Ph‐pos patients are two main factors for improved survival. Nevertheless, males in Sweden 46‐65 years with Ph‐neg B‐ALL still have poor prognosis and are thus in need of better therapeutic strategies. A high SMR for long‐term survivors emphasises that new and less toxic treatments are highly anticipated for patients with ALL of all ages.
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